STTR Phase I: Low Cost, Large Scale Production of Biocidal Micropowder by a Reversed Arc, Plasma-Fluidized Bed Reactor

STTR 第一阶段：通过反弧等离子体流化床反应器低成本、大规模生产杀菌微粉

• 批准号: 2136674
• 负责人: Vladimir Gorokhovsky
• 金额: $ 25.6万
• 依托单位: NANO-PRODUCT ENGINEERING, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2023-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136674&HistoricalAwards=false
• 关键词: STTR; Phase; Low; Cost; Large

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is based on the improvement of respiratory equipment and personal protective equipment (PPE). Commercially available face masks, gowns, filter media and other PPE are contaminated through environmental exposure, posing a threat to healthcare personnel. The proposed solution is a high-surface-area antiviral/antimicrobial micropowder which can be applied to PPE surfaces. Improved protection from infections and reduced cross-contamination may result in fewer deaths, decreased healthcare costs, and increased economic productivity. The addressable global PPE market was $23 billion in 2020 and is expected to grow through 2028, while the global disposable face mask market was valued at $792 million in 2019, and the inclusion of other types of PPE increases this estimate further. The COVID-19 pandemic is driving the demand for these products, though the applicability of the proposed technology is not limited to COVID-19. The proposed product will be material that can modify the surfaces of fabrics with active antiviral properties, leading to improvements in health and safety. The customer base is expected to be healthcare personnel, pharmaceutical and food manufacturing facilities, the public, and manufacturers of PPE, medical devices, textiles, and filters.This STTR Phase I project proposes to improve the antiviral/antimicrobial properties of respiratory equipment and PPE, which is typically only passively protective, is difficult to decontaminate and re-use, and can lead to worker exposure during changing and handling. The proposed solution is a high-surface-area micropowder, coated with an antiviral/antimicrobial coating, which can be applied to PPE surfaces. Unlike current technologies, the particle size, morphology, surface area, and topography can all be tailored for specific biocidal activity. Additionally, powder shape and surface quality can be customized to enhance adhesion. The proposed project is to develop a prototype powder product formulation that allows easy application of antiviral (copper alloy) coated particles to fabrics and other materials. This technology is based on a fluidized-bed, plasma-enhanced deposition process for synthesizing unique core-shell micropowders of metal, ceramic, or highly-shaped nanoforms of carbon, including proven biocidal materials. The synthesized microparticles will have high surface-to-weight ratios making them better suited for capturing micro-organisms while also having improved bonding to surfaces of filter media and PPE materials.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小型企业技术转移（STTR）I期项目的更广泛的影响/商业潜力基于呼吸设备和个人保护设备（PPE）的改进。市售的面具，礼服，过滤媒体和其他PPE通过环境暴露污染，对医疗保健人员构成威胁。 所提出的溶液是高表面 - 区域抗病毒/抗菌微孔，可应用于PPE表面。改善免受感染和跨污染减少的保护可能导致死亡人数减少，医疗保健成本降低以及经济生产率提高。可寻址的全球PPE市场在2020年为230亿美元，预计到2028年将增长，而全球一次性面罩市场在2019年的价值为7.92亿美元，其中包括其他类型的PPE将进一步提高这一估算。尽管所提出的技术的适用性不限于COVID-19，但COVID-19的大流行正在推动对这些产品的需求。拟议的产品将是可以改变具有主动抗病毒特性的织物表面的材料，从而改善健康和安全性。预计客户群将是医疗保健人员，药品和食品制造设施，PPE，医疗设备，纺织品和过滤器的公众和制造商。该STTR I期项目建议在典型的抗拒型和PPE的呼吸设备和PPE的抗病毒/抗菌特性，在典型的呼吸器设备和PPE中，这是一个典型的行动和重复进行的，并且可以进行跨性别的态度，并需要进行跨性别的途径。提出的溶液是高表面 - 面积微量流，涂有抗病毒/抗菌涂层，可应用于PPE表面。与目前的技术不同，粒径，形态，表面积和地形都可以针对特定的杀生物活性量身定制。另外，可以定制粉末形状和表面质量以增强粘附力。拟议的项目是开发一种原型粉末产品配方，该制剂允许轻松地将抗病毒（铜合金）涂层颗粒应用于织物和其他材料。该技术基于流化床，等离子增强的沉积过程，用于合成金属，陶瓷或高度形状的碳纳米基础的独特核心壳微量流，包括经过验证的杀菌材料。合成的微粒将具有较高的表面重量比，使其更适合捕获微生物，同时还改善了与滤波器媒体和PPE材料表面的键合。该奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子功能和广泛影响来评估CRETERIA的评估，认为NSF的法定任务值得。